Top-line results from TACTT3 trial expected in the fourth quarter Data to complement results from TACTT2 trial that are expected in August ZUG, Switzerland, June 28, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has completed patient enrollment in the Phase 3 TACTT3 clinical trial with KeyzilenTM (AM-101) in acute and post-acute inner ear tinnitus. Top-line results from the TACTT3 trial are expected in the fourth quarter of 2016. "Our Phase 3 clinical trial program for KeyzilenTM, which is comprised of TACTT2 and TACTT3, is now...
↧
Auris Medical Completes Enrollment of Phase 3 TACTT3 Trial with Keyzilen in Acute and Post-Acute ...
↧